ENDUR-ACIN® improves blood lipids and transport proteins in familial hypercholesterolemia, study shows
- ENDUR-ACIN® improves blood lipids in patients with Types IIa and IIb hyperlipoproteinemias
- Improvements in lipid transport proteins apo-A1 and apo-B also seen
- Treatment reported to be well tolerated by patients.
This clinical study was designed to assess the effects and tolerance of ENDUR-ACIN® wax matrix niacin in the treatment of dyslipidemia in 31 patients with Types IIa and IIb hyperlipoproteinemias. The study was a 6-month blinded, crossover study.
Results indicate ENDUR-ACIN® treatment reduced total cholesterol by 9-13%, reduced low-density lipoprotein (LDL) cholesterol by 12-22%, and increased high-density lipoprotein (HDL) cholesterol by 12-15%. Moreover, ENDUR-ACIN® treatment resulted in improvements in blood lipid transport proteins, including a 12-16% increase in apoprotein AI and 29% decrease in apoprotein B. Treatment was reported to be well tolerated by patients.
These findings indicate ENDUR-ACIN® has clinical value in treating familial hypercholesterolemia.